Two weeks ago Ultragenyx lost almost half its value in a single session. On Thursday it got the approval that survived the wreckage.

Ultragenyx (RARE) closed at $14.50, up 12.58% (+$1.62) on Sep 17, per StockAnalysis; Reuters had it "over 10%" in afternoon trade. Market cap: about $1.43bn.

The catalyst, with a number on it

The FDA approved FAYUVI (rebisufligene etisparvovec-hopf, formerly UX111) — the first-ever approved treatment for Sanfilippo syndrome type A. In the pivotal dataset, 17 treated patients scored 23.5 points higher on cognition than a 27-patient untreated natural-history cohort (p<0.0001), with follow-up running close to eight years. Ultragenyx says commercial supply ships to Qualified Treatment Centres within 30–60 days.

Why it's a comeback, not a breakout

This exact drug got a Complete Response Letter in July 2025 — not on efficacy, but on the chemistry-manufacturing-and-controls module and what inspectors observed at the facility, as reported by BioSpace. Ultragenyx resubmitted in February 2026, the FDA accepted in April, and the PDUFA date was Sep 19. The approval landed two days early. Separately, on Sep 3 the stock crashed ~44% when the Phase 3 Aspire trial of apazunersen in Angelman syndrome missed — a programme that carried $1.8bn-plus peak sales estimates.

The sober maths

BioPharma Dive puts FAYUVI's peak sales estimate at $120–240m. Thursday's 12.58% move added roughly $160m of market value on a $1.43bn close. So the market paid about one year of peak sales for an asset it had marked near zero — a repricing, not a melt-up. Management is aiming for profitability in 2027 off five marketed products. Other movers.

Who else gets paid

Abeona Therapeutics (ABEO) closed +4.10% at $5.59 (market cap ~$320m). Abeona sold global rights to this programme to Ultragenyx in 2022 and kept tiered royalties of up to 10% on net sales plus commercial milestones — so every FAYUVI dose shipped routes cash to a company one-fifth Ultragenyx's size. That's the actual pipe, not a vibe.

The one thing that flips it

Ultragenyx hasn't published a price. The pool is ~3,000–5,000 patients in commercially accessible geographies, median life expectancy 15 years — so list price does all the work in the revenue maths. Watch the first shipment window (30–60 days from Sep 17, so roughly mid-October to mid-November) and the Q3 report: if pricing and reimbursement land soft, $120–240m is the ceiling, not the base. The offset is the priority review voucher granted with the approval — the most recent comparable, Rocket Pharmaceuticals' voucher, closed at $180m in June 2026.

As of the Sep 17, 2026 US close (4:00 pm ET) / 9:50 am IST Sep 18. Sources: Reuters via Investing.com, Ultragenyx press release, StockAnalysis, BioSpace, BioPharma Dive, Abeona. For discussion and education only — not investment advice. Verify before acting.